207 related articles for article (PubMed ID: 22060015)
1. Decitabine immunosensitizes human gliomas to NY-ESO-1 specific T lymphocyte targeting through the Fas/Fas ligand pathway.
Konkankit VV; Kim W; Koya RC; Eskin A; Dam MA; Nelson S; Ribas A; Liau LM; Prins RM
J Transl Med; 2011 Nov; 9():192. PubMed ID: 22060015
[TBL] [Abstract][Full Text] [Related]
2. The DNA demethylating agent 5-aza-2'-deoxycytidine activates NY-ESO-1 antigenicity in orthotopic human glioma.
Natsume A; Wakabayashi T; Tsujimura K; Shimato S; Ito M; Kuzushima K; Kondo Y; Sekido Y; Kawatsura H; Narita Y; Yoshida J
Int J Cancer; 2008 Jun; 122(11):2542-53. PubMed ID: 18240144
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of systemic adoptive transfer immunotherapy targeting NY-ESO-1 for glioblastoma.
Everson RG; Antonios JP; Lisiero DN; Soto H; Scharnweber R; Garrett MC; Yong WH; Li N; Li G; Kruse CA; Liau LM; Prins RM
Neuro Oncol; 2016 Mar; 18(3):368-78. PubMed ID: 26330563
[TBL] [Abstract][Full Text] [Related]
4. MAGE-A1, MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells to facilitate cytotoxic T lymphocyte-mediated tumor cell killing.
Bao L; Dunham K; Lucas K
Cancer Immunol Immunother; 2011 Sep; 60(9):1299-307. PubMed ID: 21626030
[TBL] [Abstract][Full Text] [Related]
5. Decitabine Treatment of Glioma-Initiating Cells Enhances Immune Recognition and Killing.
Riccadonna C; Yacoub Maroun C; Vuillefroy de Silly R; Boehler M; Calvo Tardón M; Jueliger S; Taverna P; Barba L; Marinari E; Pellegatta S; Bassoy EY; Martinvalet D; Dietrich PY; Walker PR
PLoS One; 2016; 11(8):e0162105. PubMed ID: 27579489
[TBL] [Abstract][Full Text] [Related]
6. Treatment with 5-Aza-2'-Deoxycytidine Induces Expression of NY-ESO-1 and Facilitates Cytotoxic T Lymphocyte-Mediated Tumor Cell Killing.
Klar AS; Gopinadh J; Kleber S; Wadle A; Renner C
PLoS One; 2015; 10(10):e0139221. PubMed ID: 26447882
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic modulation to enable antigen-specific T-cell therapy of colorectal cancer.
Chou J; Voong LN; Mortales CL; Towlerton AM; Pollack SM; Chen X; Yee C; Robbins PF; Warren EH
J Immunother; 2012; 35(2):131-41. PubMed ID: 22306901
[TBL] [Abstract][Full Text] [Related]
8. NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-lymphocyte Responses in Patients with Myelodysplastic Syndrome.
Griffiths EA; Srivastava P; Matsuzaki J; Brumberger Z; Wang ES; Kocent J; Miller A; Roloff GW; Wong HY; Paluch BE; Lutgen-Dunckley LG; Martens BL; Odunsi K; Karpf AR; Hourigan CS; Nemeth MJ
Clin Cancer Res; 2018 Mar; 24(5):1019-1029. PubMed ID: 28947565
[No Abstract] [Full Text] [Related]
9. Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer.
Odunsi K; Matsuzaki J; James SR; Mhawech-Fauceglia P; Tsuji T; Miller A; Zhang W; Akers SN; Griffiths EA; Miliotto A; Beck A; Batt CA; Ritter G; Lele S; Gnjatic S; Karpf AR
Cancer Immunol Res; 2014 Jan; 2(1):37-49. PubMed ID: 24535937
[TBL] [Abstract][Full Text] [Related]
10. A potential role for immunotherapy in thyroid cancer by enhancing NY-ESO-1 cancer antigen expression.
Gunda V; Frederick DT; Bernasconi MJ; Wargo JA; Parangi S
Thyroid; 2014 Aug; 24(8):1241-50. PubMed ID: 24811699
[TBL] [Abstract][Full Text] [Related]
11. The molecular mechanisms of apoptosis accompanied with the epigenetic regulation of the NY-ESO-1 antigen in non-small lung cancer cells treated with decitabine (5-aza-CdR).
Inchakalody VP; Hydrose SP; Krishnankutty R; Merhi M; Therachiyil L; Sasidharan Nair V; Elashi AA; Khan AQ; Taleb S; Raza A; Yoosuf ZSKM; Fernandes Q; Al-Zaidan L; Mestiri S; Taib N; Bedhiafi T; Moustafa D; Assami L; Maalej KM; Elkord E; Uddin S; Al Homsi U; Dermime S
Eur J Pharmacol; 2023 Apr; 945():175612. PubMed ID: 36822455
[TBL] [Abstract][Full Text] [Related]
12. NY-ESO-1- and survivin-specific T-cell responses in the peripheral blood from patients with glioma.
Liu Z; Poiret T; Persson O; Meng Q; Rane L; Bartek J; Karbach J; Altmannsberger HM; Illies C; Luo X; Harvey-Peredo I; Jäger E; Dodoo E; Maeurer M
Cancer Immunol Immunother; 2018 Feb; 67(2):237-246. PubMed ID: 29058035
[TBL] [Abstract][Full Text] [Related]
13. Synergistic induction of NY-ESO-1 antigen expression by a novel histone deacetylase inhibitor, valproic acid, with 5-aza-2'-deoxycytidine in glioma cells.
Oi S; Natsume A; Ito M; Kondo Y; Shimato S; Maeda Y; Saito K; Wakabayashi T
J Neurooncol; 2009 Mar; 92(1):15-22. PubMed ID: 19030781
[TBL] [Abstract][Full Text] [Related]
14. Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy.
Srivastava P; Paluch BE; Matsuzaki J; James SR; Collamat-Lai G; Blagitko-Dorfs N; Ford LA; Naqash R; Lübbert M; Karpf AR; Nemeth MJ; Griffiths EA
Oncotarget; 2016 Mar; 7(11):12840-56. PubMed ID: 26883197
[TBL] [Abstract][Full Text] [Related]
15. Decitabine and vorinostat cooperate to sensitize colon carcinoma cells to Fas ligand-induced apoptosis in vitro and tumor suppression in vivo.
Yang D; Torres CM; Bardhan K; Zimmerman M; McGaha TL; Liu K
J Immunol; 2012 May; 188(9):4441-9. PubMed ID: 22461695
[TBL] [Abstract][Full Text] [Related]
16. Immunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts.
Srivastava P; Paluch BE; Matsuzaki J; James SR; Collamat-Lai G; Taverna P; Karpf AR; Griffiths EA
Epigenetics; 2015; 10(3):237-46. PubMed ID: 25793777
[TBL] [Abstract][Full Text] [Related]
17. Topotecan enhances immune clearance of gliomas.
Wei J; DeAngulo G; Sun W; Hussain SF; Vasquez H; Jordan J; Weinberg J; Wolff J; Koshkina N; Heimberger AB
Cancer Immunol Immunother; 2009 Feb; 58(2):259-70. PubMed ID: 18594817
[TBL] [Abstract][Full Text] [Related]
18. Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines.
Zhao Y; Zheng Z; Robbins PF; Khong HT; Rosenberg SA; Morgan RA
J Immunol; 2005 Apr; 174(7):4415-23. PubMed ID: 15778407
[TBL] [Abstract][Full Text] [Related]
19. A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma.
Krishnadas DK; Shusterman S; Bai F; Diller L; Sullivan JE; Cheerva AC; George RE; Lucas KG
Cancer Immunol Immunother; 2015 Oct; 64(10):1251-60. PubMed ID: 26105625
[TBL] [Abstract][Full Text] [Related]
20. Decitabine facilitates immune recognition of sarcoma cells by upregulating CT antigens, MHC molecules, and ICAM-1.
Krishnadas DK; Bao L; Bai F; Chencheri SC; Lucas K
Tumour Biol; 2014 Jun; 35(6):5753-62. PubMed ID: 24584817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
